Advertisement

Instant Oncology: De-ESCALaTE HPV

Published:August 20, 2021DOI:https://doi.org/10.1016/j.clon.2021.08.002

      Conflict of interest

      The authors declare no conflicts of interest.

      References

        • Mehanna H.
        • Robinson M.
        • Hartley A.
        • Kong A.
        • Foran B.
        • Fulton-Lieuw T.
        • et al.
        Radiotherapy plus cisplatin or cetuximab in low-risk human papillomavirus-positive oropharyngeal cancer (De-ESCALaTE HPV): an open-label randomised controlled phase 3 trial.
        Lancet. 2019; 393: 51-60
        • Ang K.K.
        • Harris J.
        • Wheeler R.
        • Weber R.
        • Rosenthal D.I.
        • Nguyen-Tân P.F.
        • et al.
        Human papillomavirus and survival of patients with oropharyngeal cancer.
        N Engl J Med. 2010; 363: 24-35
        • Gillison M.L.
        • Trotti A.M.
        • Harris J.
        • Eisbruch A.
        • Harari P.M.
        • Adelstein D.J.
        • et al.
        Radiotherapy plus cetuximab or cisplatin in human papillomavirus-positive oropharyngeal cancer (NRG Oncology RTOG 1016): a randomised, multicentre, non-inferiority trial.
        Lancet. 2019; 393: 40-50
        • Dowthwaite S.A.
        • Franklin J.H.
        • Palma D.A.
        • Fung K.
        • Yoo J.
        • Nichols A.C.
        The role of transoral robotic surgery in the management of oropharyngeal cancer: a review of the literature.
        ISRN Oncol. 2012; 2012: 945162
        • Yeh D.H.
        • Tam S.
        • Fung K.
        • MacNeil S.D.
        • Yoo J.
        • Winquist E.
        • et al.
        Transoral robotic surgery vs. radiotherapy for management of oropharyngeal squamous cell carcinoma – a systematic review of the literature.
        Eur J Surg Oncol. 2015; 41: 1603-1614
        • Howard J.
        • Dwivedi R.C.
        • Masterson L.
        • Kothari P.
        • Quon H.
        • Holsinger F.C.
        De-intensified adjuvant (chemo)radiotherapy versus standard adjuvant chemoradiotherapy post transoral minimally invasive surgery for resectable HPV-positive oropharyngeal carcinoma.
        Cochrane Database Syst Rev. 2018; 12: CD012939
        • Hajek M.
        • Sewell A.
        • Kaech S.
        • Burtness B.
        • Yarbrough W.G.
        • Issaeva N.
        TRAF3/CYLD mutations identify a distinct subset of human papillomavirus-associated head and neck squamous cell carcinoma.
        Cancer. 2017; 123: 1778-1790